P422: How achievable are the STRIDE-II treatment targets in real-world practise and do they affect outcome?ECCO'22Year: 2022
Authors: Routledge, E.(1);Meade, S.(1);Sharma, E.(1);Zeki, S.(1);Ray, S.(1);Anderson, S.(1);Sanderson, J.(1);Mawdsley, J.(1);Samaan, M.(1);
(1)Guys and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom;
P423: Azathioprine still remains the first step-up therapy in patients with Inflammatory Bowel Disease in low-middle income countries.ECCO'22Year: 2022
Authors: Ranjan, M.K.(1);Kumar, P.(1);Vuyyuru, S.K.(1);Kante, B.(1);Sahu, P.(1);Mundhra, S.(1);Golla, R.(1);Singh, M.(1);Virmani, S.(1);Sharma, R.(1);Panwar, R.(1);Das, P.(1);Makharia, G.(1);Kedia, S.(1);Ahuja, V.(1);
(1)All India Institute of Medical Sciences, Department of Gastroenterology and Human Nutrition, New Delhi, India;
P428: A Phase IB/IIA study of remestemcel-L, an allogeneic bone marrow derived mesenchymal stem cell product, for the treatment of medically refractory Crohn’s colitis: A preliminary analysisECCO'22Year: 2022
Authors: Lightner, A.(1);Ream, J.(2);Nachand, D.(2);Fulmer, C.(3);Regueiro, M.(4);Steele, S.(5);
(1)Cleveland Clinic, Department of Colorectal Surgery, Cleveland, United States;(2)Cleveland Clinic, Radiology, Cleveland OH, United States;(3)Cleveland Clinic, Pathology, Cleveland OH, United States;(4)Cleveland Clinic, Gastroenterology, Cleveland OH, United States;(5)Cleveland Clinic, Colorectal Surgery, Cleveland OH, United States;
P430: Longer-term tofacitinib effectiveness for the treatment of ulcerative colitis: Two-year outcomes from a UK observational cohort studyECCO'22Year: 2022
Authors: Honap, S.(1,2);Sharma, E.(1);Ray, S.(1);Mawdsley, J.(1);Anderson, S.(1);Samaan, M.(1);Pavlidis, P.(1,2);Irving, P.(1,2);
(1)Guy’s and St Thomas’ NHS Foundation Trust, IBD Centre - Department of Gastroenterology, London, United Kingdom;(2)King's College London, School of Immunology and Microbial Sciences, London, United Kingdom;
P431: Early mucosal healing at week 10 with ozanimod predicts clinical outcomes at week 52: Post hoc analysis of the phase 3 True North clinical trialECCO'22Year: 2022
Authors: Reinisch, W.(1);Axelrad, J.(2);Ahmad, H.A.(3);Pondel, M.(3);Ather, S.(3);Elegbe, A.(3);Sninsky, C.(4);Longman, R.(5);
(1)Medical University of Vienna, Gastroenterology, Vienna, Austria;(2)NYU Langone, Gastroenterology, New York, United States;(3)Bristol Myers Squibb, Department of Immunology and Fibrosis Development, Princeton, United States;(4)Digestive Disease Associates, Tbc, Gainesville, United States;(5)Weill Cornell Medicine, Tbc, New York, United States;
P433: Intravenous ustekinumab as maintenance treatment is effective in patients with partial or loss of response to optimized ustekinumab sc.ECCO'22Year: 2022
Authors: Garcia-Alvarado, M.(1);Barrio, J.(2);Sierra-Ausin, M.(3);Arias, L.(4);Fernández-Salazar, L.(5);Fuentes Coronel, A.(6);Arias García, L.(7);García-Alonso, F.J.(8);García-Prada, M.(3);Legido, J.(4);Sánchez-Hernández, J.G.(9);Muñoz, F.(10);
(1)University Hospital Salamanca, Gastroenterology, Salamanca, Spain;(2)Hospital Universitareio Río Hortega, Gastroenterology, Valladolid, Spain;(3)Hospital Universitario de León, Gastroenterology, León, Spain;(4)Complejo Asistencial de Segovia, Gastroenterology, Segovia, Spain;(5)Hospital Clínico Universitario de Valladolid, Gastroenterology, Valladolid, Spain;(6)Complejo Asistencial de Zamora, Gastroenterology, Zamora, Spain;(7)Hospital Universitario de Burgos, Gastroenterology, Gastroenterology, Spain;(8)Hospital Universitario Río Hortega, Gastroenterology, Valladolid, Spain;(9)Hospital Universitario de Salamanca, Pharmacy Service, Salamanca, Spain;(10)Hospital Universitario de Salamanca, Gastroetnerology, Salamanca, Spain;GEICYL (Group of Inflammatory Bowel Disease of Castilla y León)
P434: The PROPER study: interim analysis of a Pan-European real-world study of SB5 adalimumab biosimilar after transition from reference adalimumab in patients with Crohn’s diseaseECCO'22Year: 2022
Authors: Dignass, A.U.(1);Gisbert, J.P.(2);Bossa, F.(3);Freudensprung, U.(4);Addison, J.(5);
(1)Agaplesion Markus Hospital- Goethe University, Department of Medicine, Frankfurt, Germany;(2)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD- Universidad Autónoma de Madrid, Gastroenterology Unit, Madrid, Spain;(3)Fondazione Casa Sollievo della Sofferenza – IRCCS - San Giovanni Rotondo, Division of Gastroenterology, Puglia, Italy;(4)Biogen International GmbH, Global Head of Medical Data Science and Analytics MDSA Biosimilars, Baar, Switzerland;(5)Biogen Biosimilars Unit, Medical, Baar, Switzerland;
P435: High rate of vitamin deficiencies in patients after total proctocolectomy and pouch surgery- results from a prospective cohortECCO'22Year: 2022
Authors: Elial-Fatal, S.(1);Pfeffer-Gik, T.(1,2);Raykhel, B.(1);Friedenberg, A.(1);Margolis, L.(1);Barkan, R.(1);Ollech, J.(1,2);Yanai, H.(1,2);Wasserberg, N.(2,3);White, I.(2,3);Dotan, I.(1,2);Godny, L.(1,2);
(1)Rabin Medical Center, Division of Gastroenterology, Petah-Tikva, Israel;(2)Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel;(3)Rabin Medical Center, Division of Surgery- Colorectal Unit, Petah-Tikva, Israel;
P436: Efficacy and safety of biosimilars of anti-TNF-a in paediatric-onset Inflammatory Bowel Disease: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)ECCO'22Year: 2022
Authors: Dipasquale, V.(1);Pellegrino, S.(1);Cucinotta, U.(1);Citrano, M.(2);Graziano, F.(2);Cappello, M.(3);Busacca, A.(3);Orlando, A.(4);Accomando, S.(5);Romano, C.(1);
(1)University of Messina Hospital G. Martino, Department of Human Pathology in Adulthood and Childhood @G. Barresi@, Messina, Italy;(2)Pediatric Unit- Villa Sofia Cervello Hospital, Pediatric, Palermo, Italy;(3)Gastroenterology and Hepatology Section- Internal Medicine and Medical Specialties PROMISE- University of Palermo, Department of Health Promotion- Mother and Child Care, Palermo, Italy;(4)IBD Unit- Villa Sofia Cervello Hospital, Department of Medicine, Palermo, Italy;(5)G di Cristina Children's Hospital- University of Palermo, Pediatric Department, Palermo, Italy;Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
P437: Reoperations and long-term survival of Kock’s continent ileostomy in Inflammatory bowel disease patients: a population based national cohort study from Sweden.ECCO'22Year: 2022
Authors: Risto, A.(1);Andersson, R.E.(1);Landerholm, K.(1);Bengtsson, J.(2);Block, M.(2);Myrelid, P.(1);
(1)Linkoping University, Department of Biomedical and Clinical Sciences- Faculty of Health Sciences- Linköping University- Linköping- Sweden., Linköping, Sweden;(2)Sahlgrenska University Hospital, Department of surgery- colorectal unit., Gothenburg, Sweden;
P439: Stability of subcutaneous serum IFX (CTP13) levels between two injections and over two successive cycles in patients with Crohn's disease.ECCO'22Year: 2022
Authors: Roblin, X.(1);Bastide, L.(1);veyrard, P.(1);berger, A.E.(2);Paul, S.(2);
(1)CHU Saint Etienne - Hospital Nord, Department of Gastroenterology and Hepatology- Inserm- CIC1408, Saint Priest en Jarez, France;(2)CHU Saint Etienne - Hospital Nord, Immunology- Inserm- CIC1408, Saint Priest en Jarez, France;
P440: Loss of response and dose escalation of infliximab and adalimumab in Ulcerative Colitis patients: A Systematic Review and Meta-analysis.ECCO'22Year: 2022
Authors: Savelkoul, E.(1);Thomas, P.(1);Derikx, L.(1);Den Broeder, N.(1);Römkens, T.(2);Hoentjen, F.(3);
(1)Radboud University Medical Centre, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands;(2)Jeroen Bosch Hospital- 's-Hertogenbosch, Department of Gastroenterology and Hepatology, 's-Hertogenbosch, The Netherlands;(3)University of Alberta, Division of Gastroenterology- Department of Medicine, Edmonton, Canada;
